珠光控股(01176.HK)獲股股東融德增持480萬股
格隆匯 4 月 12日丨珠光控股(01176.HK)公佈,公司董事會獲融德投資有限公司("融德",為公司的控股股東)吿知,融德已於2021年3月31日至2021年4月9日期間在市場上購買合共480萬股公司普通股。融德分別由廖騰佳(公司副主席及執行董事)擁有36.00%、朱慶凇(公司主席及執行董事)擁有34.06%及朱沐之(執行董事)擁有29.94%。
緊隨購買事項完成後,融德將於合共48.31億股股份中擁有權益,佔於公吿日期公司已發行股本總額約67.14%。
董事會認為購買事項顯示融德對公司的前景充滿信心。融德亦表示有意於適當情況下繼續增加其於公司的持股量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.